ApoB Testing Beats LDL-C as a Cost-Effective Guide for Statin Therapy
A simulation of 250,000 adults finds using apoB goals to guide lipid-lowering therapy costs just $30,300 per QALY gained vs. non-HDL-C, making it highly cost-effective.
Summary
Researchers used a computer simulation of 250,000 statin-eligible US adults to compare three lipid targets — LDL-C, non-HDL-C, and apolipoprotein B (apoB) — for guiding intensification of cholesterol-lowering therapy. Using an apoB goal (below 78.7 mg/dL) produced the most quality-adjusted life-years and was deemed highly cost-effective at $30,300 per QALY gained compared to non-HDL-C. Non-HDL-C, in turn, dominated LDL-C by gaining 965 QALYs while actually reducing costs. At standard willingness-to-pay thresholds, apoB was the optimal strategy in 65% of probabilistic analyses. The findings suggest clinical guidelines should consider adopting apoB as the primary marker for guiding lipid-lowering decisions in primary prevention.
Detailed Summary
Cardiovascular disease remains the leading cause of death in the United States, and lipid-lowering therapy (LLT) is central to primary prevention. Yet ongoing debate persists over which lipid marker — LDL-C, non-HDL-C, or apolipoprotein B (apoB) — best guides treatment decisions. ApoB directly counts the number of atherogenic particles and is considered a superior predictor of residual cardiovascular risk compared to concentration-based measures, particularly in patients on statin therapy. Despite this, apoB testing is not universally adopted, partly due to concerns about added cost and unclear economic value. As the authors note, the cost-effectiveness of LDL-C, non-HDL-C, and apoB goals had not previously been established.
The researchers built a microsimulation model calibrated to 4,149 NHANES participants (2005–2016), projecting outcomes for a synthetic cohort of 250,000 statin-eligible, ASCVD-free US adults. Individuals received baseline statin therapy per 2018 AHA/ACC guidelines and were eligible for intensification — either high-intensity statins or ezetimibe — if they failed to meet their assigned lipid goal: LDL-C below 100 mg/dL, non-HDL-C below 118 mg/dL, or apoB below 78.7 mg/dL. Model inputs were derived from national survey data, pooled cohort studies, and published literature. Outcomes were lifetime QALYs and costs in 2025 US dollars, discounted at 3% annually.
The results favored apoB-guided therapy. Compared to LDL-C, using non-HDL-C as a target generated 965 additional QALYs (95% UI: −3,551 to 5,341) across the cohort while simultaneously reducing total costs by $2.1 million, making it a dominant strategy. The apoB goal then gained an additional 1,324 QALYs (95% UI: −2,602 to 5,669) over non-HDL-C, at an incremental cost of $40.2 million, yielding an incremental cost-effectiveness ratio (ICER) of $30,300 per QALY — well below the $120,000 willingness-to-pay threshold used in the analysis. The cost of apoB testing itself was marginal; the higher overall costs associated with the apoB strategy were driven by longer life expectancy and extended duration of preventive treatment.
In probabilistic sensitivity analyses, apoB was the optimal strategy in 65% of simulations at the $120,000 threshold, while non-HDL-C was optimal in 25%. Notably, the superiority of apoB likely reflects its ability to identify a subset of patients who appear to have met LDL-C or non-HDL-C targets yet harbor elevated atherogenic particle burdens — a discordance that can be particularly relevant in patients with metabolic syndrome or hypertriglyceridemia.
The clinical implications are significant. For both general practitioners and cardiologists, these findings provide an economic justification for ordering apoB alongside or instead of standard lipid panels in statin-treated patients. Current AHA/ACC guidelines acknowledge apoB as a secondary target but stop short of recommending it as the primary metric. This study's evidence may strengthen the case for guideline revision. Limitations include the simulation-based design, reliance on surrogate outcomes, and uncertainty in the hazard ratio estimates linking apoB to ASCVD events. The analysis also did not evaluate newer therapies such as PCSK9 inhibitors or inclisiran.
Key Findings
- ApoB-guided LLT produced 1,324 additional QALYs (95% UI: −2,602 to 5,669) vs. non-HDL-C-guided therapy across 250,000 simulated adults
- ApoB strategy had an ICER of $30,300 per QALY gained vs. non-HDL-C — well below the $120,000 US willingness-to-pay threshold
- Non-HDL-C goal dominated LDL-C by gaining 965 QALYs while reducing costs by $2.1 million
- ApoB was the optimal strategy in 65% of probabilistic sensitivity analyses at $120,000/QALY; non-HDL-C was optimal in 25%
- Cost of apoB laboratory testing was marginal; higher apoB-strategy costs were driven by longer life expectancy and extended treatment duration
- Intensification threshold for apoB was set at <78.7 mg/dL; LDL-C at <100 mg/dL; non-HDL-C at <118 mg/dL
- Model cohort was drawn from 4,149 NHANES participants (2005–2016) and scaled to 250,000 statin-eligible, ASCVD-free US adults
Methodology
This was a computer microsimulation economic evaluation modeled on 4,149 NHANES participants (2005–2016) to construct a synthetic cohort of 250,000 statin-eligible, ASCVD-free US adults. Three treatment-intensification strategies — based on LDL-C, non-HDL-C, or apoB targets — were compared using lifetime QALYs and 2025 US dollar costs, discounted at 3% annually. Model inputs were derived from national surveys, pooled longitudinal cohort studies, and published clinical literature; uncertainty was assessed with one-way and probabilistic sensitivity analyses. The primary outcome was the incremental cost-effectiveness ratio, with a willingness-to-pay threshold of $120,000 per QALY.
Study Limitations
The study relies on computer simulation rather than a randomized trial, meaning results are contingent on model assumptions and input data quality, particularly the hazard ratios linking apoB to ASCVD events. The analysis did not include newer lipid-lowering agents such as PCSK9 inhibitors or inclisiran, which could alter the cost-effectiveness landscape. Dr. Moran received NHLBI funding, Dr. Wilkins reported consultancy fees from 3M, and Dr. Kohli-Lynch reported consultancy fees from Boehringer Ingelheim, though none of these appear directly related to the study findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.